Page 2 - Epic Sciences News Today

DermTech, Inc. , a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the appointment of Mark Aguillard as chief commercial officer effective...

Breast Cancer Liquid Biopsy Market Forecast: Future Outlook and Industry Projections 2032

/PRNewswire/ -- The "Genomics Global Market Report 2023" report has been added to ResearchAndMarkets.coms offering. This report provides strategists,...

Fred Hutch biostatistician Dr. Ruth Etzioni received a seven-year Outstanding Investigator Award (OIA) from the National Cancer Institute to look at multi-cancer early detection tests, commonly referred to as liquid biopsies, and other novel diagnostic technologies..

The 56-gene ctDNA panel is a key component of DefineMBC™, the company’s comprehensive blood biopsy for metastatic breast cancerSAN DIEGO--(BUSINESS WIRE)--Epic Sciences, Inc. announced today that the company’s 56-gene ctDNA panel for genomic profiling of metastatic breast cancer is covered by the MolDX program (admi...

San Diego-based Epic Sciences has raise $24M in a Series G funding, the company said last week. According to the company, the funding was co-led by Deerfield Management and Arsenal Capital Partners, a

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

The firm is growing its sales, product marketing, and customer service teams for its multiomic metastatic breast cancer liquid biopsy test, DefineMBC.

Funding will accelerate commercial launch of DefineMBC™SAN DIEGO--(BUSINESS WIRE)--Epic Sciences, Inc. (“Epic” or “Epic Sciences”), a privately held diagnostics company, has completed a $24 million Series G which together with its $43 million Series F financing, totals $67 million raised in the last twelve months. T...

/PRNewswire/ -- The "The World Market for Liquid Biopsy, 2023" report has been added to ResearchAndMarkets.coms offering. The World Liquid Biopsy Market,...